GLAXOSMITHKLINE PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLAXOSMITHKLINE PHARMACEUTICALS have increased by 1.93% YoY .
The Earnings Per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS has increased by 11.67 % YoY. |
||
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500660|NSE : GLAXO]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹3,822 Cr | ₹3,749 Cr | ₹3,454 Cr | ₹3,252 Cr | ₹3,278 Cr |
| Expenses | ₹2,512 Cr | ₹2,572 Cr | ₹2,545 Cr | ₹2,447 Cr | ₹2,516 Cr |
| Operating Profit (Excl OI) | ₹1,309 Cr | ₹1,177 Cr | ₹909 Cr | ₹804 Cr | ₹762 Cr |
| Other Income | ₹145 Cr | ₹146 Cr | ₹123 Cr | ₹101 Cr | ₹76 Cr |
| Interest | ₹2.73 Cr | ₹1.31 Cr | ₹1.80 Cr | ₹1.81 Cr | ₹2.00 Cr |
| Depreciation | ₹66 Cr | ₹67 Cr | ₹70 Cr | ₹66 Cr | ₹68 Cr |
| Profit Before Tax | ₹1,406 Cr | ₹1,260 Cr | ₹816 Cr | ₹836 Cr | ₹779 Cr |
| Profit After Tax | ₹1,036 Cr | ₹928 Cr | ₹590 Cr | ₹608 Cr | ₹381 Cr |
| Consolidated Net Profit | ₹1,036 Cr | ₹928 Cr | ₹590 Cr | ₹611 Cr | ₹1,695 Cr |
| Earnings Per Share (Rs) | ₹61.15 | ₹54.76 | ₹34.83 | ₹36.05 | ₹100.04 |
| PAT Margin (%) | 24.54 | 22.50 | 15.59 | 17.03 | 10.59 |
| ROE(%) | 48.76 | 49.43 | 33.43 | 27.58 | 18.39 |
| ROCE(%) | 66.79 | 67.64 | 46.49 | 38.06 | 37.72 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 52,617.3 Cr |
| Revenue (TTM) | : | ₹ 3,954.9 Cr |
| Net Profit(TTM) | : | ₹ 1,068.2 Cr |
| EPS (TTM) | : | ₹ 63.1 |
| P/E (TTM) | : | 49.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAXOSMITHKLINE PHARMACEUTICALS | 6% | 19% | 9.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -4% | 15.7% |
| DIVIS LABORATORIES | 9.1% | 18.2% | 47.1% |
| TORRENT PHARMACEUTICALS | 3.6% | 3.4% | 36.4% |
| CIPLA | -1.2% | -3.3% | -10.8% |
| DR REDDYS LABORATORIES | -1.4% | 2.9% | -8% |
| MANKIND PHARMA | 0.5% | -7.4% | -7.3% |
| LUPIN | -0.7% | -10.1% | 9.6% |
| ZYDUS LIFESCIENCES | 7.8% | 6.4% | 20.3% |
GLAXOSMITHKLINE PHARMACEUTICALS Revenues
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 1.93 % |
| 5 Yr CAGR | 3.91 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹3,822 Cr | 1.93 | |
| Mar2025 | ₹3,749 Cr | 8.56 | |
| Mar2024 | ₹3,454 Cr | 6.21 | |
| Mar2023 | ₹3,252 Cr | -0.80 | |
| Mar2022 | ₹3,278 Cr | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Operating Profit
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 11.20 % |
| 5 Yr CAGR | 14.49 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,309 Cr | 11.20 | |
| Mar2025 | ₹1,177 Cr | 29.57 | |
| Mar2024 | ₹909 Cr | 12.98 | |
| Mar2023 | ₹804 Cr | 5.57 | |
| Mar2022 | ₹762 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 9.11 % |
| 5 Yr CAGR | 10.19 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 34.26% | 9.11 | |
| Mar2025 | 31.4% | 19.35 | |
| Mar2024 | 26.31% | 6.39 | |
| Mar2023 | 24.73% | 6.41 | |
| Mar2022 | 23.24% | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Profit After Tax
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 11.69 % |
| 5 Yr CAGR | -11.58 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,036 Cr | 11.69 | |
| Mar2025 | ₹928 Cr | 57.23 | |
| Mar2024 | ₹590 Cr | -3.39 | |
| Mar2023 | ₹611 Cr | -63.97 | |
| Mar2022 | ₹1,695 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 9.07 % |
| 5 Yr CAGR | 23.38 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 24.54 % | 9.07 | |
| Mar2025 | 22.5 % | 44.32 | |
| Mar2024 | 15.59 % | -8.46 | |
| Mar2023 | 17.03 % | 60.81 | |
| Mar2022 | 10.59 % | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 11.67 % |
| 5 Yr CAGR | -11.58 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹61 | 11.67 | |
| Mar2025 | ₹55 | 57.22 | |
| Mar2024 | ₹35 | -3.38 | |
| Mar2023 | ₹36 | -63.96 | |
| Mar2022 | ₹100 | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | -1.26 % |
| 5 Yr CAGR | 15.35 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 66.79% | -1.26 | |
| Mar2025 | 67.64% | 45.49 | |
| Mar2024 | 46.49% | 22.15 | |
| Mar2023 | 38.06% | 0.90 | |
| Mar2022 | 37.72% | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹3,106.1 |
| Current MarketCap | : | ₹ 52,617.3 Cr |
| Updated EOD on | : | Aug 28,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | 6% |
19% |
9.6% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
GLAXOSMITHKLINE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2.1% | 1.6% | 15.3% |
| BSE 400 MIDSMALLCAP INDEX | 0.4% | 2.2% | 7.7% |
| BSE 500 DIVIDEND LEADERS 50 INDEX | 0.3% | -0.6% | NA |
| BSE 150 MIDCAP INDEX | 0.3% | 1.9% | 8.4% |
| BSE 200 EQUAL WEIGHT | 0.1% | 0.7% | 7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 HEALTHCARE INDEX | 2% | 1.2% | 13.9% |
| NIFTY MIDSMALL HEALTHCARE | 1.8% | 1.1% | 17.5% |
| NIFTY MIDSMALLCAP400 50:50 | 0.4% | 2.3% | NA |
| NIFTY MIDSMALLCAP 400 | 0.4% | 2.1% | 9% |
| NIFTY MIDCAP 150 | 0.4% | 1.7% | 9.5% |
You may also like the below Video Courses
FAQ about GLAXOSMITHKLINE PHARMACEUTICALS Financials
How the annual revenues of GLAXOSMITHKLINE PHARMACEUTICALS have changed ?
The Revenues of GLAXOSMITHKLINE PHARMACEUTICALS have increased by 1.93% YoY .
How the Earnings per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS has increased by 11.67 % YoY .
Check out Intrinsic Value of Peers of GLAXOSMITHKLINE PHARMACEUTICALS
Compare Stock Analytics of Peers of GLAXOSMITHKLINE PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
